ECIO 2023 – Session Evaluation
IOFC 1 – Introduction and essentials of oncology (12:00-13:20)
Evaluation
IOFC 2 – Lung cancer and lung metastases (13:20-14:25)
Evaluation
IOFC 3 – Primary liver cancer and liver metastases (15:00-16:05)
Evaluation
IOFC 4 – Renal cell carcinoma (16:05-17:10)
Evaluation
IOFC 5 – Clinical practice in IO (17:10-17:40)
Evaluation
CF 112 – Ablation in other organs (08:30-10:00)
Evaluation
HDT-TA 1 – Microwave ablation (08:30-10:00)
Evaluation
CF 111 – HCC: doubts we have brought with us to 2023 (08:30-10:00)
Evaluation
HDT-TA 2 – Cryoablation (10:30-12:00)
Evaluation
SED 1 – Safe sedation application during IR procedures (basic) (10:30-12:00)
Evaluation
CF 121 – Immuno-oncology for IOs: current knowledge (10:30-12:00)
Evaluation
CF 122 – MSK: established indications (10:30-12:00)
Evaluation
SED 2 – Safe sedation application during IR procedures (basic) (12:30-14:00)
Evaluation
CF 142 – Ask me anything: views from around the world (15:00-16:00)
Evaluation
CF 141 – Meet the PI: upcoming research (15:00-16:30)
Evaluation
HDT-TA 3 – Laser ablation, IRE, electrochemotherapy (15:00-16:30)
Evaluation
SED 3 – Safe sedation application during IR procedures (advanced) (15:00-16:30)
Evaluation
SP 143 – Scientific papers 1 (16:00-16:30)
Evaluation
CF 151 – Intrahepatic cholangiocarcinoma (17:00-18:30)
Evaluation
HDT-TA 4 – Radiofrequency ablation (17:00-18:30)
Evaluation
TF 152 – Tips and tricks: case based discussion – various organs (17:00-18:30)
Evaluation
BC 153 – Liver 1 (17:00-19:00)
Evaluation
CF 211 – Metastatic CRC: hot topics (08:30-10:00)
Evaluation
SED 4 – Safe sedation application during IR procedures (basic) (08:30-10:00)
Evaluation
HDT-TA 5 – Radiofrequency ablation (08:30-10:00)
Evaluation
CF 212 – Paediatric IO: what is different in children? (08:30-10:00)
Evaluation
SED 5 – Safe sedation application during IR procedures (advanced) (10:30-12:00)
Evaluation
HL 221 – Honorary Lecture (10:30-11:15)
Evaluation
HDT-TA 6 – Microwave ablation (10:30-12:00)
Evaluation
SP 222 – Scientific papers 2 (11:15-12:00)
Evaluation
CF 211 – Metastatic CRC: hot topics (08:30-10:00)
Evaluation
SED 4 – Safe sedation application during IR procedures (basic) (08:30-10:00)
Evaluation
HDT-TA 5 – Radiofrequency ablation (08:30-10:00)
Evaluation
CF 212 – Paediatric IO: what is different in children? (08:30-10:00)
Evaluation
SED 5 – Safe sedation application during IR procedures (advanced) (10:30-12:00)
Evaluation
HL 221 – Honorary Lecture (10:30-11:15)
Evaluation
HDT-TA 6 – Microwave ablation (10:30-12:00)
Evaluation
SP 222 – Scientific papers 2 (11:15-12:00)
Evaluation
CF 312 – MSK: advanced indications (08:30-10:00)
Evaluation
HDT-RE 2 – Radioembolisation: dosimetry and administration systems (08:30-10:30)
Evaluation
CF 311 – HCC: what I would like to read in the new guidelines (08:30-10:00)
Evaluation
HDT-TA 9 – Laser ablation, IRE, electrochemotherapy (08:30-10:00)
Evaluation
HDT-MSK 1 – Musculoskeletal oncologic interventions (10:30-12:00)
Evaluation
HDT-TA 10 – Radiofrequency ablation (10:30-12:00)
Evaluation
CF 321 – Why an IO should be on the tumour board: renal cancer (10:30-12:00)
Evaluation
SP 323 – Scientific papers 3: pre-clinical and clinical (10:30-12:00)
Evaluation
TF 322 – AI: from monitoring tools to robotics (10:30-12:00)
Evaluation
VL 341 – How I do it – video learning (15:00-16:30)
Evaluation
CF 342 – Neuroendocrine liver metastases (15:00-16:30)
Evaluation
HDT-TA 11 – Microwave ablation (15:00-16:30)
Evaluation
HDT-MSK 2 – Musculoskeletal oncologic interventions (15:00-16:30)
Evaluation
IA 343 – IASIOS: Helping make Interventional Oncology a mainstream discipline in cancer care (15:00-16:00)
Evaluation
SP 352 – Scientific papers 4: liver (17:00-18:30)
Evaluation
CF 351 – Planning percutaneous tumour ablation – what we can learn from radiotherapy and what we need to develop ourselves (17:00-18:30)
Evaluation
HDT-TA 12 – Cryoablation (17:00-18:30)
Evaluation
BC 353 – Liver 3 (17:00-19:00)
Evaluation
CF 412 – Emergencies in IO (08:30-10:00)
Evaluation
CF 411 – Why an IO should be on the tumour board: metastatic colorectal cancer (08:30-10:00)
Evaluation
MM 421 – Morbidity & Mortality (10:30-12:00)
Evaluation